Second Clinical Site Opened in Ph 1 Clinical Study of JBZ-001
“We are excited to add a second center to our first-in-human trial, serving the Mountain Region and allowing more geographical access to patients,” said Tamara Jovonovich, PhD, Chief Executive Officer of Jabez Biosciences. “We are currently enrolling our second dose cohort in the dose-escalation portion of the study. Opening the trial at a second site expands our reach and our hope of delivering best-in-class therapies that address the unmet needs of cancer patients. JBZ-001’s unique mechanism of action, which targets multiple pathways beyond nucleotide depletion, offers hope for a broad spectrum of oncological indications, and we are eager to see its potential unfold in this trial.”
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib